A weekly round-up of the
latest coverage in psychedelics.
Receive the free weekly digest straight to your inbox every week
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
November 18 – 24, 2024
New Association Launches to Expand Patient Access to Psychedelic Medicines
Press Release ↗
Founding members include Compass Pathways, B. More Inc., Lykos Therapeutics and MindMed. The group’s Scientific Advisors include Peter Hendricks, Paul Hutson, Sandeep Nayak and Jennifer Jones.
$PSY Sells Out, Raising $2 Million for Psychedelic Science
mirror.xyz ↗
PsyDAO, a decentralised autonomous organisation that aims to fund psychedelics research and art, has raised around $2m following its initial mint of PSY tokens.
Pα+ Psychedelic Bulletin #181
Psychedelic Alpha ↗
- Last-Minute Rule Changes, Opt-Outs, Ahead of Colorado’s Psychedelics Program Launch
- Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move
- DEA Extends Telemedicine Rules for Controlled Substances Through 2025
- Vermont Psychedelic Therapy Advisory Working Group Kicks Can Down the Road
- Other Stories including: $PSY Sells Out, Raising $2 Million for Psychedelic Science; Johns Hopkins Launches Psilocybin Microdosing Study; New Industry Association Launches; Kentucky Ibogaine Initiative Figurehead Relocates Effort to REID Foundation; and Lawmakers in Georgia Consider Spending Up To $5 Million on Psychedelic Research for Veterans. Read all about it…
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Press Release ↗
The company reports 12-mo efficacy data from a Phase 2 study of its deuterated psilocin candidate, CYB003, in major depressive disorder (MDD). The results are impressive, with 100% of patients responders and 71% in remission at the 12-month mark. The sample is small, however, with just 8 participants represented in the cut of data, 7 of which received two 16 mg doses (the remaining participant received just one dose). The company announced the commencement of its Phase 3 program last week.
November 11 – 17, 2024
Can Canada’s psychedelic drug developers shake off the sector’s bad trip?
The Globe and Mail ↗
Pα+ Psychedelic Bulletin #180
Psychedelic Alpha ↗
- Massachusetts’ Psychedelics Ballot Question Post-Mortem Begins
- Cybin Commences Phase 3 Program of Deuterated Psilocin, CYB003, in Major Depressive Disorder
- Opt-Out Trend Continues: Oregon’s Local Jurisdictions Push Back on Psilocybin Access
- CaaMTech Claims It’s Solved Functional Unblinding, But Won’t Tell Us How
- Compass Says Phase 3 Readout Punt Is About Durability, Not Unblinding
- Lykos-Funded Study Finds MDMA-AT Cost Effective with Drug Priced at $12k per Session
- Other Stories including: RFK Jr. Scores HHS Position; UC Davis Researchers Claim Separation of DOI’s Hallucinogenic and Anxiolytic Effects; Relmada Launches Ph 1 Study of Low-Dose Psilocybin; Numinus Sells Clinics; and more…
November 4 – 10, 2024
October 28 – November 3, 2024
Final Stretch for Question 4: Controversy, Advocacy, and Celebrity Voices Shape Psychedelic Vote
Psychedelic Alpha ↗
Jack Gorsline shares the latest view from Massachusetts, where psychedelics advocates and detractors are hoping to sway voters to mark a ‘yes’ or ‘no’ next to Question 4 next week. The Yes campaign feels that coverage by The Harvard Crimson was unfair, a key anti-Question 4 campaigner appears to have misrepresented his group’s potential participation in a debate, the No campaign receives its first major donation, and more…
OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question 4
Psychedelic Alpha ↗
‘It changed my life’: Eliza Dushku pushing to legalize certain psychedelics in Massachusetts
Boston 25 (YouTube) ↗
Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff
Psychedelic Alpha ↗
This morning, Compass Pathways announced delays to both of its Phase 3 studies, as well as a major reduction in force that sees its preclinical programs and digital tools effectively shelved. Here, we provide our analysis along with coverage of the company’s earnings call and associated discussion.
Pα+ Psychedelic Bulletin #179
Psychedelic Alpha ↗
- VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control
- A Look at the Latest Oregon Psilocybin Services Complaints
- Zuranolone’s MDD Journey Ends
- Tryp Therapeutics Raises $6M to Forward IV Psilocin Candidate
- Psylo and Co. Win $3M Grant to Develop Neuroplastogens
- Other Stories
Backed by $15m in NIDA Funding, NYU and B.More Team Up to Trial Psilocybin for Opioid Use Disorder
Psychedelic Alpha ↗
We speak to Carey Turnbull and Michael Bogenschutz about an ambitious new study.
Submissions Open for Nature Scientific Reports’ Psychedelics Collection (Closing 31st July, 2025)
Nature Scientific Reports ↗
Pα+
An insider’s guide to the business,
policy and science of psychedelics.
Basic
Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams
Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.
Benefits
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||